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Transcervical carotid stenting with flow reversal is
a safe technique for high-risk patients older than
70 years
Beatriz Alvarez, MD, PhD,a Manuel Matas, MD, PhD,a Marc Ribo, MD, PhD,b Jordi Maeso, MD,a
Xavier Yugueros, MD,a and Jose Alvarez-Sabin, MD, PhD,b Barcelona, Spain
Background: Recent evidence regarding carotid revascularization advises against carotid angioplasty and stenting (CAS)
in patients aged >70 years with conventional risk for carotid endarterectomy (CEA). The poor outcome of transfemoral
CAS in this age group may be explained by the anatomic characteristics of the aortic trunk and supra-aortic vessels in
elderly patients, as well as by a high prevalence of aortic arch atheromatosis. Transcervical CAS with flow reversal for
cerebral protection avoids these unfavorable characteristics. This study analyzed the short-term and middle-term results
of transcervical CAS with flow reversal in patients aged >70 years at high risk for CEA.
Methods: Between January 2006 and January 2011, 219 cases of >70% carotid artery stenosis in high-risk patients aged
>70 years (55.7% asymptomatic and 44.3% symptomatic) were treated by transcervical CAS. All patients underwent
complete neurologic examination by a stroke neurologist before and after the procedure. Primary end points were stroke,
death, or myocardial infarction (MI), technical success, and complications at 30 days. During follow-up, we analyzed the
rate of restenosis >50% and ipsilateral stroke. Data were collected prospectively and outcome was analyzed in all cases,
including technical failures.
Results: The 30-day combined stroke/death/MI rate was 2.2% (stroke, 1.8%; stroke/death, 2.2%; and MI, 0.45%). In
symptomatic patients, stroke/death/MI was 5.1% (stroke, 4.1%; stroke/death, 5.1%). None of the asymptomatic
patients suffered stroke, MI, or death postoperatively. Technical success was 96.3% (four inability to cross lesion, two
major common carotid dissections, one failed preangioplasty, one stent thrombosis). One cervical hematoma required
surgical drainage. At follow-up (18.8 16.9 months), cumulative (standard error) incidence of>70% restenosis was 3%
(1%) at 1 year and 8% (3%) at 2 and 3 years. Only one patient experienced ipsilateral stroke during follow-up. Overall
survival (standard error) was 94% (2%) at 1 year and 90% (3%) at 2 and 3 years.
Conclusions: In our experience, transcervical CAS with flow reversal is a safe technique for treating carotid stenosis in
patients aged >70 years. We believe that avoiding the aortic arch and tortuous supra-aortic vessels is responsible for the
favorable results in this study. (J Vasc Surg 2012;55:978-84.)
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aThe currently available evidence on carotid artery re-
vascularization based on meta-analyses and systematic re-
views of randomized clinical trials comparing carotid artery
endarterectomy (CEA) and carotid angioplasty and stent-
ing (CAS) recommend CEA as the treatment of choice.
Carotid stenting remains as the first indicated treatment for
patients with high perioperative cardiac risk and those with
unfavorable anatomic factors for CEA.1
In a recent pooled analysis2 including 3433 patients
with symptomatic carotid stenosis enrolled in the Endar-
terectomy Versus Angioplasty in Patients with Symptom-
atic Severe Carotid Stenosis (EVA-3S)3 trial, the Stent-
Supported Percutaneous Angioplasty of the Carotid Artery
versus Endarterectomy (SPACE)4 trial, and the Interna-
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978ional Carotid Stenting Study (ICSS),5 an increased risk of
troke was associated with advanced age in patients treated
ith transfemoral CAS. In younger patients, CASmay be as
afe as CEA, although the rate of recurrent stenosis in this
opulation (potentially higher after stenting) and the long-
erm stroke rate remain to be defined. In patients aged70
ears, however, it is recommended to avoid CAS because
he estimated risk of stroke/death in patients undergoing
AS in this age group is double that of patients treated with
EA.
The warnings about elevated rates of stroke/death in
lder patients undergoing transfemoral CAS emerged
hen the interim results from the lead-in phase of the
arotid Revascularization Endarterectomy vs Stenting
rial (CREST)6 demonstrated that the periprocedural risk
f stroke and death in CAS increased with age, reaching
2.1% in patients aged80 years. Later, the SPACE4 study
ndicated a higher risk in patients aged 75 years, and the
REST7 investigators additionally reported an interaction
etween age and treatment efficacy, which decreased in
atients aged 70 years.
Several hypotheses have been proposed8,9 to explain
he unfavorable results of transfemoral CAS in patients of
dvanced age. An altered configuration of the aortic arch,
ogether with a higher prevalence of aortic atherosclerosis
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Volume 55, Number 4 Alvarez et al 979and greater tortuosity of the vessels in this population,
provide a biologic explanation for the correlation between
age and the incidence of periprocedural neurologic events
in CAS-treated patients.
Nonetheless, our preliminary study in octogenarian
patients10 showed that treatment with transcervical CAS
with flow reversal for cerebral protection is as safe as CEA at
short-term in this population. This technique avoids the
biologic mechanisms potentially responsible for the higher
rate of events in older patients treated by transfemoral
access and additionally provides neuroprotection by de-
creasing the number of microemboli during the proce-
dure.11
The aim of this study was to analyze the short-term and
medium-term outcome of transcervical carotid stenting
with flow reversal in patients aged70 years. Our hypoth-
esis is that manipulation of the aortic arch and supra-aortic
trunks is responsible for the high incidence of CAS-related
neurologic morbidity in these patients and that avoidance
of this manipulation will yield better results.
METHODS
From January 2006 to January 2011, 627 carotid re-
vascularizations were done in our institution, including 325
CEA and 302 CAS procedures. In this study, we analyzed
the outcome of patients aged70 years with70% carotid
stenosis treated by transcervical CAS with flow reversal,
which was indicated for 219 cases in 212 patients. These
patients, who were at high risk for CEA according to the
criteria of the Stenting and Angioplasty with Protection in
Patients at High Risk for Endarterectomy (SAPPHIRE)
trial,12 were prospectively and consecutively included in the
study. The anatomic factors that excluded transcervical
CAS were kinking of the distal internal carotid very close to
the stenosis, atheromatosis of the common carotid with
30% stenosis, and presence of the string sign (pseudo-
occlusion). The hospital ethics committee approved the
study and all patients gave informed, written consent for
participation.
All data were collected prospectively. In addition to
standard epidemiologic variables (eg, age and sex), the data
collection protocol included the classic cardiovascular risk
factors of hypertension, diabetes mellitus, hypercholester-
olemia, and smoking, defined according to standard crite-
ria. We also investigated the presence of severe pulmonary
disease and severe cardiac disease. An independent neurol-
ogist classified patients as neurologically symptomatic or
asymptomatic, using the reporting standards of the Society
for Vascular Surgery.13
The degree of carotid stenosis was determined by
Doppler ultrasound (DUS) imaging (Philips HD 11 Both-
ell, Wash) of the supra-aortic trunks. Magnetic resonance
angiography was performed to study the morphology of
the lesion, determine the presence of kinking, evaluate
intracranial circulation, and confirm the degree of stenosis
when DUS examination was considered unreliable. The
brain parenchyma was examined by magnetic resonance
imaging. In the preoperative workup, transcranial Doppler QTCD) imaging (Spencer PMD-100; Spencer Technolo-
ies, Seattle, Wash) was performed to evaluate the cerebral
emodynamic reserve (considered exhausted when the
ean middle cerebral artery velocity increased 20% after
0 seconds of apnea),14 presence of high-intensity transient
ignals (HITS), defined as microembolic signals of 300
s duration and amplitude 3 dB higher than the back-
round blood flow signal,15 and any associated intracranial
esions. In all cases, TCD monitoring was used during the
rocedure to determine the presence of HITS and flow
ariations in the middle cerebral artery, as we described in a
revious study.11 A complete neurologic examination was
erformed by a stroke neurologist before and after the
rocedure in all patients.
All procedures were performed by the same vascular
urgeon, who had extensive experience in transcervical CAS
50 procedures/year). The technique used, which was
rst described by Criado et al,16 is explained in detail in our
revious study.17 Briefly, through a minimal incision at the
ase of the neck, a shunt is established between the internal
ugular vein and the common carotid artery. Proximal
cclusion of the common carotid is then carried out,
chieving flow inversion in the internal carotid artery and
stablishing a cerebral protection system before crossing
he carotid lesion. The technique is performed only under
ocal anesthesia infiltration, not cervical plexus block. Sys-
emic heparin is administered to maintain the activated
lotting time (ACT) between 250 and 300 seconds. In the
ase of significant bradycardia, atropine (0.5-1 mg) is in-
ected, and if spasm of the distal carotid occurs, intra-
rterial nitroglycerin (100-200 g) can be used.
All patients were prescribed acetylsalicylic acid (100
g/d) and clopidogrel (75mg/d) for at least 4 days before
he procedure. In cases of noncompliance with this treat-
ent, a 300-mg loading dose of clopidogrel was adminis-
ered 24 hours before treatment. Double antiplatelet ther-
py (aspirin 100 mg/d and clopidogrel 75 mg/d) was
aintained for the first 30 days and, thereafter, clopidogrel
75 mg/d) indefinitely was prescribed.
The periprocedural complications (30 days) recorded
ere subsequent ipsilateral stroke, death, myocardial in-
arction (MI), and local and systemic complications. The
eriprocedural neurologic evaluation was performed by an
ndependent neurologist in accordance with the National
nstitutes of Health Stroke Scale (NIHSS),18 as follows:
ransient ischemic attack (TIA), any neurologic, ocular, or
erebral deficit lasting 24 hours; minor stroke, any neu-
ologic, ocular, or cerebral deficit lasting 24 hours and
ncreasing the NIHSS score by 3 points; and major
troke, any deficit increasing the NIHSS score by 3
oints. Ischemic neurologic events were differentiated
rom cerebral hemorrhage.
Acute MI was defined as anginal chest pain plus tro-
onin T elevation greater than twice the upper limit of the
eference value, creatine kinase (CK-MB) fraction exceed-
ng the normal reference range, or development of new
-waves on electrocardiography (ECG).
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April 2012980 Alvarez et alLocal complications recorded included peripheral
nerve palsy or dysfunction and cervical hematomas requir-
ing surgical drainage. Among systemic complications were
cardiac, respiratory, and renal abnormalities.
Technical success was defined by 30% residual steno-
sis on arteriography at completion of surgery. Procedurally
related complications included dissection of the common
carotid artery, inability to cross the lesion, failed angio-
plasty, and stent thrombosis within the first 24 hours.
Clinical and DUS follow-up studies were performed at
24 hours, at 1, 3, 6, and 12 months, and yearly thereafter.
We assessed the presence of ipsilateral or contralateral
stroke and death due to any cause during follow-up. He-
modynamically significant poststenting carotid stenosis was
established on a peak systolic velocity ratio of 2, and a
hemodynamically significant change was defined by pro-
gression to 4 or carotid occlusion. Peak systolic veloci-
ties were measured in the common carotid artery at 2 cm
from the bifurcation and at the site of maximum in-stent
stenosis.
Statistical analysis. The data analysis was performed
on all patients who entered the protocol, including those in
which the initially planned technique of transcervical CAS
could not be completed. A descriptive analysis was carried
out with the variables obtained and comparisons were
performed with SPSS 15.0 software (SPSS Inc, Chicago,
Ill). Survival rates were analyzed using the Kaplan-Meier
product limit survival method, and the log-rank test was
used to determine statistical significance between groups.
Simple Cox proportional hazard models were performed to
analyze differences for continuous variables. A value of P
.05 was considered statistically significant.
RESULTS
The 212 participating patients were a mean age of
79.9  4.9 years (range, 70-92 years), 168 (79.2%) were
men, and 134 were aged 80 years. The distribution of
cardiovascular risk factors and associated diseases is summa-
Table I. Epidemiologic and clinical variables of the
patients treated
Mean  SD
Variable No. (%)
Age, years 79.9  4.9
Male sex 168 (9.2)
Hypertension 181 (85.3)
Diabetes mellitus 77 (36.3)
Hypercholesterolemia 114 (53.7)
Smoking 14 (6.6)
Ischemic heart disease 116 (54.7)
Pulmonary disease 50 (23.5)
Renal failure 29 (13.6)
Symptomatic 97 (44.3)
Contralateral stenosis 50% 81 (36.9)
Intracranial lesion 71 (32.4)
Decreased or exhausted
hemodynamic reserve 20 (9.1)rized in Table I. The main indications for CAS were ele- lated cardiac risk in 120 patients (54.7%), severe obstruc-
ive pulmonary disease in 50 (22.8%), contralateral
aryngeal nerve palsy and nonviable femoral access in five
2.2%), recurrent stenosis after CEA in six (2.7%), recurrent
tenosis after CAS in three (1.3%), prior cervical radiother-
py in six (2.7%), and a distal internal carotid lesion in five
2.2%). Patients were excluded for the following anatomic
isk factors: five for kinking of the distal internal carotid very
lose to the stenosis, three with atheromatosis of the com-
on carotid 30%, and three with string sign.
Carotid stenosis 70% was symptomatic in 97 cases
44.3%) and asymptomatic in 122 (55.7%). Within the
symptomatic group, an associated intracranial lesion was
resent in 22 of 122 patients (18%), contralateral carotid
cclusion in eight (6.5%), decreased or exhausted cerebral
emodynamic reserve in six (5%), and HITS in the preop-
rative TCD examination in two (1.6%).
All patients except one received adequate antiplatelet
herapy before revascularization. The mean duration of the
rocedure was 40 minutes (range, 25-60 minutes), and
he mean interval with flow reversal was 15  5 minutes.
he mean volume of contrast used was 25  15 mL, and
ean duration of fluoroscopy was 6  4 minutes.
Arteriographic monitoring showed flow reversal in all
ases. Predilation of the lesion with 3- 2-cm Viatrac Plus
alloons (Guidant, Santa Clara, Calif) indicated when the
tenotic lumen was 1.5 mm measured by DUS was per-
ormed in 12 cases (5.4%). The following self-expanding
tents were implanted: Carotid Wallstent (Boston Scien-
ific, Natick, Mass) in 123 (58.2%), Acculink (Guidant,
anta Clara, Calif) in 81 (38.3%), and ViVEXX Carotid
tent (C.R. Bard, Inc, Murray Hill, NJ) in seven (3.3%).
ostangioplasty dilation was carried out in all patients. All
atients were treated with atropine before angioplasty.
Significant distal internal carotid spasm occurred in
our patients, with successful reversal by intra-arterial nitro-
lycerin administration in one and spontaneous resolution
fter guidewire withdrawal in the remaining three. In three
ases (1.3%), intolerance to flow reversal occurred, which
as resolved by declamping the common carotid artery and
apidly completing the procedure. There were no neuro-
ogic sequelae after these events.
The procedure was successfully completed in 211 of the
19 cases, yielding a technical success rate of 96.3%. In four
ases, the procedure could not be performed because it was
mpossible to cross the very extensive, preocclusive internal
arotid lesion. The patients’ clinical condition was such that
he risk of CEA could be assumed; hence, conversion to this
rocedure was decided. In two patients, a major dissection
as seen in the common carotid artery after completing
tent placement. Because the dissections were close to the
ntroducer sheath, it did not seem advisable to attempt
ndovascular treatment, and instead, a bypass from the
ommon carotid artery to the distal internal carotid was
erformed. Neither patient experienced neurologic symp-
oms at the end of these procedures. In another patient,
reangioplasty of the lesion was not achieved because of a
arge calcification. Conversion to conventional surgery was
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Volume 55, Number 4 Alvarez et al 981decided and CEA was carried out. This patient, who was
symptomatic and had severe bilateral stenosis and a high
cardiologic risk, died of aMI 48 hours after the CEA. Thus,
mortality in patients who required conversion to conven-
tional surgery was 14.2%.
Stent thrombosis was seen on DUS imaging follow-up
at 24 hours in one patient who showed no neurologic
symptoms and had considerable respiratory comorbidity
with an elevated risk for CEA. It was decided not to
intervene to recover stent patency. In the remaining pa-
tients, there were no cases of 30% residual stenosis on
arteriography at completion of the procedure. One large
cervical hematoma was observed, which required surgical
drainage, and two patients presented with transient laryn-
geal nerve palsy, secondary to impregnation of the nerve
with local anesthesia. DUS imaging confirmed stent pa-
tency in the 211 patients (99.5%) undergoing the proce-
dure, with the exception of the patient mentioned above.
Patients were discharged from the hospital 48 hours after
the intervention.
The combined rate of stroke, death, and MI in the first
30 days was 2.2%, comprising four strokes (1.8%; one TIA
and three major strokes) and one patient with severe MI
who died at 48 hours after the procedure (0.45%). In the
symptomatic patients, the stroke/death/MI rate was 5.1%
(all patients who presented with a neurologic event were
symptomatic, and the patient who had MI and died also
belonged to this group). Therefore, the stroke rate in
symptomatic patients was 4.1% and the stroke/death rate
was 5.1%. None of the asymptomatic patients suffered
stroke, death, or MI within the first 30 days after the
procedure (Table II). Among the 134 patients aged 80
years, three suffered stroke (stroke rate in this population
2.2%), and all three were symptomatic. The patient who
died of MI was also an octogenarian.
Mean follow-up was 18.8 16.9months, and only one
ipsilateral stroke occurred during the follow-up period (Fig
1). Therefore, ipsilateral stroke-free survival at 1, 2, and 3
years was 99% (standard error [SE], 1%) in the three peri-
ods. The cumulative incidence of restenosis 70% was 3%
(1%) at 1 year, and 8% (1% and 3%, respectively) at 2 and 3
years. The cumulative incidence (SE) of restenosis 50%
was 19% (3%) at 1 year and 27% (4%) at 2 and 3 years (Fig
2). Presence of chronic obstructive pulmonary disease was
associated with restenosis (P  .04). Overall survival (SE)
in the patient series was 94% (2%) at 1 year and 90% (3%) at
Table II. Clinical outcome at 30 days by intention-to-
treat analysisa
Outcome All patients, % Symptomatic, %
Stroke rate 1.8 (1 TIA, 3 major
strokes)
4.1
Stroke/death rate 2.2 (1 death) 5.1
Stroke/death/MI rate 2.2 (1 MI) 5.1
MI, Myocardial infarction; TIA, transient ischemic attack.
aNo events occurred in asymptomatic patients.2 and 3 years (Fig 3). oISCUSSION
The results of this study indicate that transcervical CAS
ith flow reversal can be safely performed in symptomatic
nd asymptomatic patients aged 70 years. This is a high-
isk patient population, in particular regarding medical
omorbidities. CAS is a less aggressive technique than CEA
or carotid revascularization; the transcervical approach
ircumvents the problems encountered with transfemoral
ccess in elderly patients, and flow reversal provides effec-
ive neuroprotection. Thus, our results suggest that the
ndications for CAS can be extended to include this pop-
lation. Although the restenosis rate at middle-term
ollow-up was high, it was not associated with a high rate of
eurologic events. Therefore, it seems that transcervical
arotid stenting is effective for preventing stroke, the main
ig 1. Kaplan-Meier estimates of stroke-free survival. S.E., Stan-
ard error.
ig 2. Kaplan-Meier estimates of restenosis-free survival. S.E,
tandard error.bjective of carotid revascularization.
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April 2012982 Alvarez et alFor the indication of carotid stenting, we followed the
SAPPHIRE criteria, which includes three situations that
currently remain under discussion. One is the general def-
inition of high risk for CEA and the other two are related to
the strategy used in patients with a hostile neck or contralat-
eral laryngeal nerve palsy. The series presented is a high-risk
patient population, in particular regarding medical comor-
bidities; that is, all presented one or more of the comorbid
conditions listed in SAPPHIRE.
Because the definition of high risk for CEA is contro-
versial, one might ask whether a patient who can tolerate
transcervical CASmight also tolerate CEA.We believe that
the technique we use for CAS is less aggressive than for
CEA for several reasons: exposure of the common artery
and jugular vein is achieved through a very small incision
(3 cm), whereas CEA needs a much larger incision and
there is extensive dissection of the common carotid and
external and external carotid arteries, which increases the
risk of neurologic injury; in CEA, the carotid body is
manipulated, implying a greater possibility of hemody-
namic disturbance; lastly, in transcervical CAS, only local
infiltration of anesthesia is used, not cervical plexus block
as in CEA, and this also implies a lower procedure-
associated risk.
We believe the transcervical approach should be
avoided in patients with a hostile neck (tracheostomy,
previous radical neck surgery, or previous cervical radio-
therapy). Transcervical CAS was only performed in six
patients with previous cervical radiotherapy and at the start
of the series; currently, we do not use the technique in these
patients because of greater difficulty in accessing the vessels.
In the five patients with contralateral nerve palsy, an ab-
sence of femoral pulse led us to choose the transcervical
procedure. Nonetheless, the transfemoral approach should
be used in patients with a hostile neck or contralateral
laryngeal nerve palsy whenever possible.
The periprocedural stroke/death/MI rate in our over-
Fig 3. Kaplan-Meier estimates of survival. S.E, Standard error.all series of symptomatic and asymptomatic patients was.2% vs the 5.2% rate reported in the CREST trial,7 which
ncluded both patient populations in the transfemoral
tenting group. On individual analysis of the outcomes
stroke, 1.8%; MI, 0.45%; and death, 0.45%), our results
ere also somewhat lower than those in the CREST study
stroke, 4.1%; MI, 1.1%; death, 0.7%). The difference in
ample size should be considered when comparing the
esults of the two studies, as well as the fact that CREST7
eports an interaction between age and the benefits of
reatment. Patients aged 70 years presented with signifi-
antly poorer results than younger patients in CREST, and
his supports the assertion that the outcome in our series is
uite good. Although the stroke rate in our series was
igher in octogenarians (2.2%) than in septuagenarians, it
emains favorable compared with the results of other stud-
es, such as CREST,7 in which the stroke rate in patients
ged 80 years was 12.1%.
Comparison of our results in symptomatic patients with
hose from other studies including this population also
hows a favorable rate of periprocedural stroke/death using
he transcervical approach with flow reversal: 5.1% in our
atients vs 9.6% in EVA-3S,3 6.8% in SPACE,4 and 7.4% in
CSS.5 In a recent pooled analysis of the interaction with
ge in the patients included in these three trials,2 the risk of
troke/death in patients aged70 years was double that of
ounger patients (12% vs 5.8%). On the basis of our com-
ined rate of stroke/death/MI (2.2%), we believe it is
easonable to affirm that carotid stenting can be safely
erformed in patients aged 70 years.
Although our study examined a high-risk population,
o stroke, MI, or death occurred in the asymptomatic
atients, a more favorable outcome than the 2.5% of these
vents reported in CREST,7 2.3% in the Asymptomatic
arotid Atherosclerosis Study (ACAS),19 and 3.1% in the
symptomatic Carotid Surgery trial (ACST).20 Nonethe-
ess, although the results were excellent in asymptomatic
atients, we believe that in asymptomatic octogenarians,
nly those at relatively low risk and with perspectives for
easonably long survival (5 years) should be considered
or CAS.
An elevated percentage of our patients had medical
omorbidities, including 54.8% with elevated cardiac risk
nd 22.8% with severe obstructive pulmonary disease, al-
hough these figures are somewhat lower than those of the
opulation in the SAPPHIRE12 study, also performed in
igh-risk patients (85.8% and 17%, respectively). The
troke/death/MI rate was also low in that trial: 2.1% in
ymptomatic patients and 5.4% in asymptomatic. As men-
ioned, the criteria of high risk for CEA are controversial.
onetheless, one of the seven patients who required con-
ersion to surgery in our series died after CEA, which may
e an indication that our selection criteria did not overes-
imate high-risk status.
We attribute the good periprocedural results we ob-
ained with transcervical CAS to several factors:
● Transcervical access circumvents the unfavorable bio-
logic circumstances present in patients of advanced
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Volume 55, Number 4 Alvarez et al 983age: a higher prevalence of aortic arch atheromatosis,
alterations in the configuration of the aortic arch, and
greater tortuosity of the supra-aortic vessels.8,9
● With flow reversal, protection is established before the
lesion is crossed, and the number of microemboli is
significantly reduced.11
● All procedures were performed by the same vascular
surgeon with extensive experience in this technique. In
keeping with the opinion of the authors of CREST7
and SAPPHIRE,12 we believe that the volume of
procedures performed and degree of experience of the
surgeon are important predictors of outcome with this
surgery.
Stroke prevention at middle-term and long-term is a
fundamental objective of carotid revascularization, and
CAS seems to be effective in this regard. The ipsilateral
stroke rate at 3 years of follow-up was 1% and did not differ
substantially from the rates reported in CREST7 (2% at 4
years), SPACE21 (2.2% at 2 years), or EVA-3S22 (1.26% at
4 years). The rate of post-CEA recurrent stenosis was
somewhat higher than that of post-CEA restenosis. The
70% restenosis rate in our series was 8% at 3 years and was
similar to that reported in SPACE21 (10.7% at 2 years), but
higher than that of EVA-3S22 (3.3% at 3 years). Nonethe-
less, given the low rate of neurologic events during follow-
up, the post-CAS restenosis that occurred seemed to be
benign, as is the case of recurrent stenosis post-CEA.
The cumulative incidence of death by any cause during
follow-up was 10% and we consider that overall survival was
quite high in this elderly population with a high prevalence
of medical comorbidities.
CONCLUSIONS
In our experience, carotid revascularization by stenting
can be safely performed in patients aged 70 years if a
transcervical approach is used with flow reversal for cerebral
protection. In patients with a hostile neck or contralateral
laryngeal nerve palsy, however, we believe that a femoral
approach would be more appropriate. The increased life
expectancy in the general population leads to a greater
number of candidates for this procedure with increasingly
more numerous medical comorbidities. Because transcervi-
cal CAS is less surgically aggressive than CEA, this tech-
nique will benefit the at-risk population requiring carotid
revascularization.
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